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Abstract
Background. Recently, we identified specific N- and
6-O-sulphated heparan sulphate (HS) domains on
activated glomerular endothelial cells. In this study,
we evaluated in lupus nephritis the expression of
different HS domains on glomerular endothelium
and in the glomerular basement membrane (GBM).
Methods. The expression of specific glomerular HS
domains and the presence of immunoglobulins (Ig)
were determined by immunofluorescence staining of
kidney sections of patients with nephritis due to
systemic lupus erythematosus (SLE) and MRL/lpr
lupus mice. The expression/presence of glomerular
HS domains and Ig was also evaluated after eluting
Ig from renal sections of lupus mice using two elution
methods, and in renal sections of lupus mice treated
with heparinoids.
Results. Both MRL/lpr mice and patients with lupus
nephritis showed a decreased expression of HS
in the GBM. The expression of N- and 6-O-sulphated
HS domains on glomerular endothelium was decreased
in MRL/lpr mice, but increased in SLE patients.
MRL/lpr mice had more extensive glomerular Ig
deposits than SLE patients. After elution of Ig,
the glomerular endothelial expression of N- and
6-O-sulphated HS domains in MRL/lpr mice was
recovered and even increased above normal levels,
while the expression of HS in the GBM was restored to
normal levels. Treatment with heparinoids prevented
Ig deposition and preserved the expression of glomer-
ular HS domains at normal levels in lupus mice.
Conclusion. The expression of specific HS domains on
glomerular endothelium and in the GBM is changed
during lupus nephritis due to masking by Ig deposits
and induction of inflammatory N- and 6-O-sulphated
HS domains.
Keywords: albuminuria; glomerular basement
membrane; glomerular endothelial cells;
glomerulonephritis; heparan sulphate; heparinoids;
systemic lupus erythematosus
Introduction
A hallmark of systemic lupus erythematosus (SLE) is
the development of anti-nuclear autoantibodies, in
particular anti-chromatin autoantibodies, that include
anti-dsDNA, anti-histone and nucleosome-specific
antibodies [1,2]. Furthermore, nucleosomes can be
detected in the circulation of SLE patients and lupus
mice, which may be the result of an aberrant apopto-
sis and/or an insufficient clearance of apoptotic
cells/debris [2]. About 50% of patients with SLE will
develop glomerulonephritis, which is characterized
by granular deposits of immunoglobulins (Ig) in the
mesangium and along the glomerular capillary wall,
and the glomerular influx of leucocytes, leading to
albuminuria, haematuria and impairment of renal
function [3].
Heparan sulphate proteoglycans (HSPGs) are com-
posed of a core protein with covalently linked linear
heparan sulphate (HS) carbohydrate side chains. These
HS side chains can consist of up to 150 disaccharide
units of glucosamine–uronic acid residues that can be
sulphated at the N-position, 2-, 3- and/or 6-O-position,
and epimerized at the C-5-position [4]. The possible
combinations of modifications within one HS chain
gives rise to an enormous structural diversity, which
is important for the specific binding of a myriad
of factors. HSPGs are intrinsic constituents of the
extracellular matrix, like the glomerular basement
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membrane (GBM), and responsible for the majority
of anionic sites in the GBM [5]. It is assumed that
the negatively charged HS in the GBM is important for
the charge-selective filtration [5,6], although recently
its contribution has been questioned [7]. Furthermore,
HSPGs are expressed at the cell surface of virtually all
cells and are involved in many biological processes,
which are often mediated by the binding of relevant
factors via their HS side chain. HS expressed at cell
surfaces plays an important role during inflammatory
processes by binding to chemokines, cytokines, selec-
tins and integrins [8,9]. Several studies demonstrated
that in particular N- and 6-O-sulphated HS domains
on activated endothelial cells may serve as ligands
for L-selectin and Mac-1, which are expressed on
leucocytes [4,8–10].
Based on previous work, we hypothesized that in
SLE, binding of anti-dsDNA and nucleosome-specific
antibodies to nucleosomes in the circulation leads to
neutralization of negative charges on the nucleosome,
thus making it overall more positive [11]. This masking
of negative charge in the nucleosome leads to an
enhanced binding/deposition of the anti-nucleosome/
nucleosome immune complexes to the negatively
charged HS in the GBM mediated by the positively
charged N-terminal histone tails within the nucleosome
[11–13]. Recently, it was demonstrated with EM
co-localization studies that deposited Ig is bound
to extracellular chromatin bound to the GBM [14].
The amount of Ig deposits along the capillary loops
and the degree of albuminuria correlated significantly
with a decreased expression of HS in the GBM, while
the expression of the HSPG core protein agrin
remained unaltered [15]. Previously, we showed that
treatment of MRL/lpr lupus mice with heparin or
low molecular weight (LMW) heparinoids prevented
albuminuria, and specifically, the deposition of
nephritogenic immune complexes in the GBM.
Most likely, the administered heparinoids bound to
the anti-nucleosome/nucleosome immune complexes,
thus preventing the binding to HS, and thereby, the
deposition of these immune complexes in the glomer-
ular capillary wall [16].
In the current study, we evaluated the expression
of different HS domains either in the GBM or on
glomerular endothelial cells in murine and human
lupus nephritis. The glomerular expression/presence
of specific HS domains and Ig was also evaluated after
elution of Ig from kidney sections of lupus mice
following two methods, and in kidney sections of lupus
mice treated with heparinoids.
Methods
Animals
Kidney sections were obtained as previously described from
18-week-old MRL/lpr mice, which were divided into three
groups depending on their degree of albuminuria: ‘no
albuminuria’ (NA, albustix <300mg/ml), ‘short albuminuria’
(SA, albustix >1000 mg/ml, albuminuria for a period shorter
than 7 days) and ‘long albuminuria’ (LA, albustix >1000 mg/
ml, albuminuria for a period of 14–21 days) [15]. Kidney
sections of age-matched MRL þ/þ mice were included as a
control. At this stage these mice had no renal abnormalities
and no albuminuria. Kidney sections of 21-week-old MRL/
lpr mice, which were treated daily with LMW heparin or
phosphate buffered saline (PBS) from week 8 until week 21,
were obtained as described previously [16]. The local Animal
Ethics Committee of the Radboud University Nijmegen
Medical Centre approved all animal experiments.
SLE patients
Kidney biopsies from SLE patients with proliferative lupus
nephritis (ISN/RPS class III or IV) (Table 1) were collected
at the Division of Nephrology, Radboud University
Nijmegen Medical Centre, which was approved by the local
Human Ethics Committee of the Radboud University
Nijmegen Medical Centre.
Immunofluorescence staining
Indirect immunofluorescence stainings were performed on
2mm cryostat renal sections. Sections were fixed in ice-cold
acetone for 10min and incubated with primary antibodies
diluted in PBS containing 1% bovine serum albumin (BSA,
Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands)
and 0.05% sodium azide (IF-buffer) for 45min at room
temperature. The expression of HS in the GBM was
evaluated by staining with the anti-HS mouse monoclonal
Table 1. Clinical characteristics of SLE patients
Patient no Sex Age Duration
of disease
(months)
Serum
creatinine
(mmol/l)
Urinary
protein
(g/24 h)
Classification
lupus nephritis
(ISN/RPS 2003)
C3 (g/l) C4 (g/l) Anti-dsDNA
(U/ml)
1 F 37 18 100 2.7 IV-S (A/C) 1.10 0.17 350
2 F 42 6 120 2.1 IV-S (A/C) 0.95 0.20 250
3 F 36 120 142 6.4 IV-G (A) 0.35 0.09 59
4 F 18 24 71 2.2 III (A/C)þV 0.62 0.12 600
5 F 21 2 172 15 IV-G (A/C) 0.46 0.13 17
6 F 20 2 65 2.8 III (A/C)þV 0.80 0.15 79
7 M 22 1 54 2.0 III (A/C) 0.27 0.02 847
8 F 43 0 66 2.4 III (A)þV 0.37 0.02 577
9 F 18 0 64 0.4 III (A) 0.49 0.09 706
10 M 26 51 90 0.7 III (A/C) 0.37 0.04 212
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antibody JM403 (0.1 mg/ml), which recognizes HS in the
GBM [17]. The glomerular endothelial expression of N- and
6-O-sulphated HS domains was evaluated by double staining
with the VSV-tagged single chain anti-HS antibodies
AO4B08, EW3D10 and EW4G2, recognizing N- and
6-O-sulphated HS domains (10–50mg/ml) [18,19] and
a rat anti-mouse CD31 (PECAM-1) monoclonal anti-
body (0.1 mg/ml, BD Biosciences, Alphen aan den Rijn,
The Netherlands). To prevent non-specific mouse Ig staining
on mouse renal sections, the mouse-on-mouse kit
(Brunschwig Chemie, Amsterdam, The Netherlands) was
used according to the manufacturer’s protocol. Sections were
washed in PBS and for detection incubated with the
appropriate Alexa 488-conjugated secondary antibodies
(5 mg/ml, Molecular Probes, Leiden, The Netherlands) or
anti-VSV-Cy3 (2 mg/ml, Sigma-Aldrich Chemie) in IF-buffer
for 45min at room temperature. The presence of glomerular
Ig was evaluated by incubation with the appropriate Alexa
488-conjugated anti-Ig antibodies (5 mg/ml, Molecular
Probes). Subsequently, sections were washed in PBS, post-
fixed with 1% paraformaldehyde in PBS, washed in PBS,
and embedded in VectaShield mounting medium H-1000
(Brunschwig Chemie). The slides were evaluated by fluores-
cence microscopy (Leica DM4000B fluorescence microscope,
Leica Microsystems B.V., Rijswijk, The Netherlands) and
photographed with the Leica DFC300 FX digital camera
(Leica Microsystems). The staining intensities of 25 glomeruli
were scored on a scale between 0 and 10 on blinded sections
by two independent observers. The r values between the
two observers ranged from 0.8–0.95. Six mice were analysed
in each group.
Elution of Ig deposits
To study whether Ig could be eluted and HS staining could
be subsequently restored, we tested two elution procedures
on renal sections of MRL/lpr mice. Method I: Non-fixed
2 mm cryostat sections were submerged in 220ml solution of
0.15M glycine with 5M urea, pH 2.8, of 48C for exactly 2 h,
and subsequently, extensively washed in PBS at 208C.
Method II: Non-fixed 2 mm cryostat sections were submerged
in 220ml solution of 0.15M glycine with 5M urea, pH 2.8, of
208C with a subsequent cooling-down at 48C for exactly 2 h
and followed by extensive washing in PBS at 208C. Kidney
sections of MRL þ/þ mice were also subjected to the
same elution procedures and used as controls to correct for
Ig-independent effects of the elution procedures on the
integrity of the HS domains as probed by the anti-HS
antibodies. For each anti-HS antibody, the ratio was
calculated by dividing the expression of untreated sections
of MRL þ/þ mice by the expression of MRL þ/þ sections
that were eluted. To evaluate the effect of Ig on the elution
procedure, renal sections of normal C57/BL6 mice loaded
with excessive amounts of purified rabbit anti-mouse GBM
IgG were subjected to elution procedure II, as described
above. Staining of anti-HS antibodies was compared with
sections that were not subjected to elution procedure II.
Statistical analysis
Values are expressed as means  SEM and significance was
determined by Mann-Whitney U testing using GraphPad
Prism, version 4.0 software (GraphPad Software, Inc.,
San Diego, CA). P values <0.05 were considered as
significant.
Results
The expression of HS domains in the GBM and on
glomerular endothelial cells is decreased in MRL/lpr
mice with albuminuria
We evaluated the expression of HS in the GBM and on
glomerular endothelial cells of 18-week-old MRL/lpr
lupus mice with no albuminuria (NA), short albumin-
uria (SA) or long albuminuria (LA), and in age-
matched MRL þ/þ controls. Probing with the anti-HS
antibody JM403, which recognizes N-unsubstituted
HS domains especially in the GBM, revealed a
significant decrease of HS in the GBM of the LA
group compared with the MRL þ/þ control group,
while HS expression in the GBM of the NA and SA
groups was similar to the MRL þ/þ group, although
there was a trend to a lower expression in the SA group
(Figure 1A–E) [15]. Double staining with an anti-CD31
antibody and the anti-HS antibodies AO4B08,
EW3D10 and EW4G2 [18,19], which recognize
N- and 6-O-sulphated HS domains, revealed a
decreased glomerular endothelial expression of the
N- and 6-O-sulphated HS domains in the LA and
SA groups compared with the MRL þ/þ group, while
the expression in the NA group was unaffected
(Figure 2A–C). As will be discussed, we have evidence
that these N- and 6-O-sulphated HS domains are
associated with activated glomerular endothelial cells,
and thus can be considered as inflammatory HS
domains. We also evaluated glomerular Ig deposits,
which revealed an increased presence of Ig along the
capillary wall in both the SA and LA group compared
with the MRL þ/þ group, while the Ig deposition
in the NA group was similar to the MRL þ/þ group
(Figure 2D). Our data suggest that Ig may mask
specific HS domains in both the GBM and on
glomerular endothelial cells.
Masking of HS domains in the GBM and on
glomerular endothelial cells by Ig in MRL/lpr
mice with albuminuria
Previously, we obtained indirect evidence that in SLE,
HS in the GBM was masked by Ig deposits [11–13,15].
However, at that time we could not unmask the HS
domain in the GBM that is recognized by the antibody
JM403 by eluting Ig from renal sections. Most likely,
the elution procedure led to destruction of the HS
domain [15]. To remove Ig, we originally incubated
renal sections of LA MRL/lpr mice in 0.15M glycine
with 5M urea, pH 2.8, with a starting temperature of
48C for exactly 2 h at 48C (‘Ig elution method I’), which
indeed resulted in removal of Ig, as previously found
[15], but not in the full reappearance of HS along the
capillary wall, i.e. in the GBM as measured by JM403
and on glomerular endothelial cells as measured
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by EW3D10 (Figure 3A and B). In the current study,
we developed a slightly modified Ig elution procedure,
in which we incubated renal sections of MRL þ/þ
mice and MRL/lpr mice in 0.15M glycine with 5M
urea, pH 2.8, with a starting temperature of 208C
followed by a cooling-down period of exactly 2 h at
48C (‘Ig elution method II’). The use of Ig elution
method II, revealed also the removal of Ig along the
capillary wall from sections of SA and LA MRL/lpr
mice down to the levels present in MRL þ/þ and NA
MRL/lpr mice. Moreover, by using elution method II,
we were now able to recover (partially) the staining for
HS in the GBM as measured by JM403 and on
glomerular endothelial cells as measured by EW3D10,
while elution method I hardly recovered glomerular
HS expression (Figure 3A and B). Next, we estimated
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Fig. 1. Expression of heparan sulphate in the glomerular basement membrane of lupus and control mice. The expression of HS in the GBM
of MRL þ/þ control mice (A), MRL/lpr lupus mice with no albuminuria (B), short (C) and long albuminuria (D) was determined by probing
with the monoclonal anti-HS antibody JM403. Staining intensity along the capillary wall was scored semi-quantitatively. Magnification
400. The expression of HS in the GBM was significantly decreased in MRL/lpr mice with long albuminuria (E). P< 0.05 compared with
MRL þ/þ control mice. GlcNH3þ, N-unsubstituted glucosamine; NA, no albuminuria; SA, short albuminuria; LA, long albuminuria.
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the direct effect of the Ig elution method I and II on the
integrity of HS domains by subjecting sections of
control MRL þ/þ mice to elution method I and II
followed by staining with the various anti-HS
antibodies. This revealed that the staining by the
anti-HS antibody JM403 was rather insensitive to
the newly developed Ig elution method II, while the
staining by the anti-HS antibodies EW3D10, AO4B08
and EW4G2 decreased about 1.5-fold after elution
method II (Figure 4A and B). Knowing this, we
subjected sections of LA MRL/lpr mice to the Ig
elution method II, followed by staining with the
anti-HS antibodies JM403 (Figure 5A), EW3D10,
AO4B08 and EW4G2 (Figure 5B–D), which revealed
a nearly complete recovery of expression of HS
domains in LA MRL/lpr mice compared with MRL
þ/þ mice. However, when we corrected the staining
intensities of the anti-HS antibodies for the direct effect
of the elution method on the binding of the anti-HS
antibodies (Figure 4B), we noticed a complete recovery
of HS expression in the GBM as measured by JM403,
while the expression of inflammatory N- and
6-O-sulphated HS domains on glomerular endothelial
cells as measured by EWD3D10, AO4B08 and
EW4G2, respectively, was about 1.5-fold higher
than in MRL þ/þ mice (Figure 5A–D).
One could argue that Ig plays a possible protective
role on the effects of elution procedure II on the
integrity of the HS domains on renal sections with
lupus nephritis. This could raise doubts whether the
‘correction factor’ for the effect of the elution method
on the integrity of HS domains as determined on MRL
þ/þ kidney sections is applicable for lupus sections.
Therefore, we have performed immunofluorescence
stainings with the anti-HS antibodies after Ig elution
method II on mouse renal sections loaded with
excessive amounts of rabbit anti-GBM IgG, which
mimics the glomerular Ig deposition in lupus nephritis.
It appeared that the effect of the elution procedure on
the integrity of the HS domains on these sections
loaded with excessive amounts of rabbit anti-GBM
IgG was similar, i.e. the correction factor was
1.5-fold, to the effect of the elution procedure on
renal sections of MRL þ/þ mice, in the presence of
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Fig. 2. Expression of N- and 6-O-sulphated heparan sulphate domains on glomerular endothelial cells and Ig deposits along the capillary wall
in lupus and control mice. The glomerular endothelial expression of N- and 6-O-sulphated HS domains in MRL þ/þ mice and MRL/lpr
lupus mice with no albuminuria, short and long albuminuria was determined by double staining for CD31 and N- and 6-O-sulphated HS
domains with the respective anti-HS single chain antibodies EW3D10 (A), AO4B08 (B) and EW4G2 (C). The epitopes of the single chain
antibodies are given within parentheses. Co-staining intensities were scored semi-quantitatively and revealed a significantly decreased
expression of N- and 6-O sulphated HS domains in MRL/lpr lupus mice with short and long albuminuria (A-C). Ig deposition along the
capillary wall was significantly increased in MRL/lpr mice with short and long albuminuria (D). P< 0.05 compared with MRL þ/þ control
mice. GlcNS, N-sulphated-glucosamine; S, sulphate; IdoA, iduronate; GlcA, glucuronate; NA, no albuminuria; SA, short albuminuria; LA,
long albuminuria.
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low amounts of Ig (data not shown). In summary,
Ig masks specific HS domains in the GBM and on
glomerular endothelial cells in MRL/lpr mice with
albuminuria. Moreover, elution of Ig revealed an
increased expression of the inflammatory N- and 6-O
sulphated HS domains on glomerular endothelial cells.
Decreased expression of HS in the GBM and increased
expression of inflammatory N- and 6-O-sulphated HS
domains on glomerular endothelial cells in SLE patients
Analogous to the staining performed in murine lupus
nephritis, we stained renal sections of SLE patients
with proliferative lupus nephritis (n¼ 10; Table 1) and
healthy controls (n¼ 10) with JM403, EWD3D10,
AO4B08 and EW4G2. As previously demonstrated
[11], the expression of HS in the GBM, as measured
with JM403, was decreased in SLE patients compared
with healthy controls (Figures 6A and 7A). However,
and in contrast to mice with lupus nephritis, the
expression of inflammatory N- and 6-O-sulphated HS
domains on glomerular endothelial cells as mea-
sured with EWD3D10, AO4B08 and EW4G2, and
co-stained with anti-CD31, was significantly increased
in SLE patients compared with healthy controls
(Figures 6B and 7B–D). Evaluation of Ig deposits
along the capillary wall revealed less abundant Ig
deposition in SLE patients compared with mice with
lupus nephritis (compare Figure 7E and Figure 2D).
Four human renal biopsies were subjected to Ig elution
method II, followed by staining with the anti-HS
antibody JM03, which revealed a nearly complete
recovery of HS expression in the GBM (data not
shown). This suggests that the masking of HS in the
GBM by Ig in SLE patients is comparable to that in
lupus nephritis mice, while the increased expression
of inflammatory N- and 6-O-sulphated HS domains
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Fig. 3. Elution of Ig from renal sections of lupus mice unmasks the expression of glomerular heparan sulphate domains. Ig was eluted
from renal sections of MRL/lpr mice with long albuminuria by two different methods as detailed in the Methods section and in the text (A).
Both Ig elution method I and II lead to the removal of Ig (B), but only Ig elution method II leads to reappearance of HS in the GBM,
as measured by staining with JM403, and on glomerular endothelial cells, as measured by staining with the anti-HS antibody EW3D10 (A).
P< 0.05 compared with MRL þ/þ control mice. #P< 0.05 compared with untreated sections. Magnification 400. GlcNH3þ,
N-unsubstituted glucosamine; GlcNS, N-sulphated-glucosamine; S, sulphate; NA, no albuminuria; SA, short albuminuria; LA,
long albuminuria.
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on glomerular endothelial cells is not masked by Ig in
SLE patients to such a degree as in lupus mice.
Treatment of MRL/lpr mice with LMW heparin
prevents changes in the expression of HS domains
in the GBM and on glomerular endothelial cells
Previously, we showed that treatment of MRL/lpr
mice with LMW heparin prevents the deposition of
nucleosome/anti-nucleosome immune complexes along
the capillary wall and the development of albuminuria
[16]. Indeed, MRL/lpr mice treated with LMW
heparin showed an almost normal expression of HS
in the GBM (Figure 8A), whereas the expression of
the inflammatory N- and 6-O-sulphated HS domains
on glomerular endothelial cells was preserved
(Figure 8B–D). This preserved HS expression in the
GBM and on glomerular endothelial cells was asso-
ciated with a significant decrease in Ig deposits along
the capillary wall compared with PBS-treated MRL/lpr
mice (Figure 8E). Notably, treatment with LMW
heparin not only prevented Ig deposition and masking
of HS domains, but also prevented the increased
expression of the inflammatory N- and 6-O-sulphated
HS domains on glomerular endothelial cells as
observed in untreated MRL/lpr mice (Figure 5B–D)
and SLE patients (Figure 7B–D). In summary,
treatment of murine lupus nephritis with LMW
heparin prevents Ig deposition along the capillary
wall, is associated with a normal expression of HS in
the GBM and prevents inflammation-induced upregu-
lation of the N- and 6-O-sulphated HS domains on
glomerular endothelium.
Discussion
Previously, we found indirect evidence that in
lupus nephritis, HS in the GBM was masked by Ig,
which leads to the reduction of functional anionic sites
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Fig. 4. Effect of the Ig elution procedure on the integrity of heparan sulphate domains in the GBM and on glomerular endothelial cells.
This effect was determined by subjecting renal sections of MRL þ/þ control mice to the Ig elution procedures (methods I and II) followed
by staining with the indicated anti-HS antibodies. Representative photographs of renal sections before and after Ig elution probed with the
anti-HS antibodies JM403 and EW3D10, respectively, are shown. Magnification 400 (A). Semi-quantitative scoring of the staining
intensities of the anti-HS antibodies JM403, EW3D10, AO4B08 and EW4G2 revealed that the epitope of JM403 is slightly affected, while the
epitopes of EW3D10, AO4B08 and EW4G2 are significantly affected by the Ig elution method II (B). P< 0.05 compared with untreated
sections. GlcNH3þ, N-unsubstituted glucosamine; GlcNS, N-sulphated-glucosamine.
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in the GBM and is associated with the development of
albuminuria [15]. We also showed that the amount of
Ig deposited along the capillary wall was significantly
correlated with the degree of albuminuria. However,
we never could prove unequivocally that Ig masked
HS in the GBM, since elution of Ig from renal sections
did remove Ig, but also affected the integrity of the
HS domain in the GBM as evaluated by the mono-
clonal antibody JM403 [15]. In the current study,
we developed a modified Ig elution method that had a
less detrimental effect on the integrity of HS domains
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Fig. 5. Elution of Ig from renal sections of MRL/lpr mice unmasks heparan sulphate domains in the GBM and on glomerular endothelial
cells. Elution of Ig (method II) from renal sections of MRL/lpr mice with long albuminuria unmasked the expression of HS in the GBM,
as measured by staining with the anti-HS antibody JM403 (A), and the expression of N- and 6-O-sulphated HS domains on glomerular
endothelial cells, as measured by staining with the respective anti-HS antibodies EW3D10 (B), AO4B08 (C) and EW4G2 (D). Correction of
staining intensities for the effect of the Ig elution procedure on the epitopes of the anti-HS antibodies (Figure 4), revealed that the expression
of the N- and 6-O-sulphated HS domains on glomerular endothelial cells was higher than in MRL þ/þ control mice, while the HS expression
in the GBM was similar to MRL þ/þ control mice. P< 0.05 compared with untreated sections. #P< 0.05 compared with MRL þ/þ control
mice. GlcNH3þ, N-unsubstituted glucosamine; GlcNS, N-sulphated-glucosamine; S, sulphate; IdoA, iduronate; GlcA, glucuronate;
LA, long albuminuria.
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Fig. 6. Expression of heparan sulphate domains in the GBM and
on glomerular endothelial cells in a patient with SLE nephritis
and in a healthy control. Representative photographs showing
the decreased expression of HS in the GBM (A) and the slightly
increased expression of N- and 6-O-sulphated HS domains on
glomerular endothelial cells (B) of a SLE patient and a healthy
control, as measured by staining with the anti-HS antibody JM403
(A) or co-staining with anti-CD31 (green) and the anti-HS antibody
EW3D10 (red) (B). Magnification 400.
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as measured by anti-HS antibodies. Using this Ig
elution method, we now clearly could demonstrate that
in murine lupus nephritis, HS domains in the GBM
and on glomerular endothelial cells are indeed masked
by deposited Ig. This is also the case for expression of
HS in the GBM in SLE patients (data not shown),
which indicates that in lupus nephritis HS in the GBM
is masked by Ig. Elution of Ig from renal sections of
mice with lupus nephritis also revealed the unmasking
of specific N- and 6-O-sulphated HS domains on
glomerular endothelial cells as measured by specific
anti-HS antibodies. Actually, when we corrected for
the effect of the Ig elution procedure on the integrity
of these HS domains, the glomerular endothelial
expression of these N- and 6-O sulphated HS domains
was even higher than in control mice. We have ample
evidence that these N- and 6-O-sulphated HS domains
can be considered as inflammatory HS domains on
glomerular endothelial cells [20]. First, the expression
of these N- and 6-O-sulphated HS domains by
glomerular endothelial cells in vitro is increased after
activation with proinflammatory cytokines like tumour
necrosis factor (TNF)-a and interleukin (IL)-1b.
Second, these N- and 6-O-sulphated HS domains
play a crucial role in the adhesion of granulocytes to
glomerular endothelial cells as measured in a static
in vitro adhesion system. Third, the glomerular
endothelial expression of these N- and 6-O-sulphated
JM403 (GlcNH3+)A
*
St
ai
ni
ng
 in
te
ns
ity
 (A
U)
B EW3D10 (GlcNS6S)
*
St
ai
ni
ng
 in
te
ns
ity
 (A
U)
Healthy controls SLE patients
EW4G2 (GlcNS6S-GlcA-GlcNS6S)D
*
St
ai
ni
ng
 in
te
ns
ity
  (A
U)
Healthy controls SLE patients
C AO4B08 (GlcNS6S-IdoA2S-GlcNS6S)
Healthy controls SLE patients
*
St
ai
ni
ng
 in
te
ns
ity
 (A
U)
0
2
4
6
8
10
0
2
4
6
8
10
0
2
4
6
8
10
Healthy controls SLE patients
0
2
4
6
8
10
0
2
4
6
8
10
Ig
 d
ep
os
its
 (A
U)
E
*
Healthy controls SLE patients
Fig. 7. Analysis of the expression of heparan sulphate domains in the GBM and on glomerular endothelial cells in SLE patients and healthy
controls. The expression of HS in the GBM, as measured by staining with the anti-HS antibody JM403, was significantly decreased in SLE
patients (A). The expression of N- and 6-O-sulphated HS domains on glomerular endothelial cells, as measured by co-staining with anti-
CD31 and the respective anti-HS antibodies EW3D10 (B), AO4B08 (C) and EW4G2 (D), was significantly increased. Ig deposits along the
capillary wall were also significantly increased in SLE patients (E). P< 0.01 compared with healthy controls. GlcNH3þ, N-unsubstituted
glucosamine; GlcNS, N-sulphated-glucosamine; S, sulphate; IdoA, iduronate; GlcA, glucuronate.
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HS domains is also increased during the acute phase of
experimental anti-GBM glomerulonephritis [21]. In the
current study, we also could show activation of
glomerular endothelial cells in lupus mice with
albuminuria by measuring an increased glomerular
endothelial expression of intercellular adhesion mole-
cule (ICAM)-1 (data not shown), which also has been
described by others [22]. Interestingly, without Ig
elution we already could observe an increased
glomerular endothelial expression of the inflammatory
N- and 6-O-sulphated HS domains in SLE patients.
Apparently, there was less deposited Ig in the renal
sections of the SLE patients when compared with lupus
mice, which could explain that there was a lower
degree or even absence of masking of glomerular
endothelial HS domains in SLE patients. On the other
hand, although the amount of Ig deposited along the
capillary wall in SLE patients was lower compared
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Fig. 8. The expression of glomerular heparan sulphate domains is preserved in lupus mice treated with low molecular weight (LMW) heparin.
The expression of HS in the GBM, as measured by staining with JM403 (A), and the expression of N- and 6-O-sulphated HS domains on
glomerular endothelial cells, as measured by co-staining with anti-CD31 and the respective anti-HS antibodies EW3D10 (B), AO4B08 (C)
and EW4G2 (D), was preserved in MRL/lpr mice treated with LMW heparin and similar to that in MRL þ/þ control mice (dotted line).
The amount of Ig along the capillary wall in MRL/lpr mice treated with LMW heparin was the same as in MRL þ/þ control mice (dotted
line). (E), P< 0.05 compared with MRL/lpr mice treated with PBS. GlcNH3þ, N-unsubstituted glucosamine; GlcNS, N-sulphated-
glucosamine; S, sulphate; IdoA, iduronate; GlcA, glucuronate.
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with lupus mice, the reduction in expression of HS in
the GBM was similar to that in lupus mice. This may
be explained by the preferential deposition in the GBM
of the nucleosome/anti-nucleosome immune complexes
[14]. In summary, in both murine lupus nephritis and
in patients with proliferative SLE nephritis we could
show an increased glomerular endothelial expression
of inflammatory N- and 6-O-sulphated HS domains.
Recently, we have shown that the HS-specific
b(1–4)-endoglucuronidase enzyme heparanase (HPSE)
that cleaves HS at specific sites [23,24] may be involved
in the pathogenesis of proteinuria in overt diabetic
nephropathy by degradation of HS in the GBM [25].
In the current study, we also evaluated the glomerular
HPSE expression, which appeared to be slightly,
but not significantly, increased in SLE patients with
proliferative lupus nephritis compared with healthy
controls (data not shown). Since we previously showed
a normal content of glomerular HS in MRL/lpr mice,
irrespective of the degree of proteinuria [15], we suggest
that the increased N- and 6-O-sulphated HS expression
by glomerular endothelium is due to an altered
modification process of HS during lupus nephritis.
Previously, we have shown that treatment of
pre-diseased lupus mice with LMW heparin prevented
the binding of immune complexes to the GBM and
delayed the development of lupus nephritis [16].
In addition, we now could show that this treat-
ment prevents the increase in expression of N- and
6-O-sulphated HS domains. The anti-inflammatory
effect of treatment with LMW heparin, i.e. the
prevention of the increased glomerular endothelial
expression of the inflammatory N- and 6-O-sulphated
HS domains, may be the result of both a reduced
deposition of immune complexes and a reduced
glomerular influx of leucocytes.
In conclusion, the expression of specific HS domains
in the GBM and on glomerular endothelial cells is
changed during lupus nephritis. These changes are due
to both masking by Ig and by inflammatory stimuli,
while treatment with heparinoids preserves the expres-
sion of HS domains in the glomerulus by preventing
both processes.
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